Search
for

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community The story of RU58841/PSK3841

      in Research/Science 1 year ago
      RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

      community Having Ru58841 mailed to my house

      in Research/Science  1 upvotes 1 month ago
      RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
      The story of RU58841/ PSK3841

      community The story of RU58841/ PSK3841

      in Research  622 upvotes 1 year ago
      RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

      community Anagenic is trying to compound Gt20029

      in Treatment  56 upvotes 3 years ago
      The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.